



COVID - 19 and European Pharmaceutical Law

In the wake of the COVID-19 pandemic, the **European Pharmaceutical Law Review (EPLR)** would like to establish a forum for expert insights into the EU and Member State responses to this public health crisis, focussing on pharmaceutical and medical device law and policy.

We invite contributions of 1.500 – 3.000 words for online, open-access publication. The aim of these contributions should be to provide up-to-date insights and opinion pieces for a general audience with a legal and public policy background, who are not necessarily pharma law experts but have a basic knowledge of the EU and its regulatory frameworks in this area.

Potential topics for contributions include:

- Vaccine development, trials and authorisation
- Treatment development, trials and authorisation
- Responses to medical device shortage
- Impact on medicines accessibility
- Regulatory cooperation in the pandemic response
- Opinions on EMA and European Commission COVID-19 activities
- Insights from the Member States: pharma and medical devices

The pieces will be published on the **EPLR** website and promoted via social media and through the **EPLR** network. In order to provide current information and cut down waiting time due to review and publication processes, the pieces are not peer reviewed.

However, contributors are invited to submit full articles based on their contribution for publication in the **EPLR**, which will be subject to peer-review before acceptance for publication and are required to conform to the author guidelines available at: www.lexxion.eu/eplr/author-guidelines.

Contributions will be accepted on a rolling basis.

The editorial team looks forward to discussing your proposals and receiving your submissions. For further enquiries, please contact:



Jakob McKernan
Executive Editor
mckernan@lexxion.eu
+49-30-81 45 06-10